OBJECTIVES: The purpose of this study was to investigate whether patients who received methylene blue as treatment for vasoplegia during cardiac surgery with cardiopulmonary bypass had decreased morbidity and mortality. DESIGN: Retrospective analysis. SETTING: Single tertiary care university hospital. PARTICIPANTS: Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008. INTERVENTIONS: With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue. Two hundred twenty-six patients were identified who met the inclusion criteria for the study. Fifty-seven of these patients had received methylene blue for vasoplegia. The authors collected data on preoperative and intraoperative variables as well as outcomes. MEASUREMENTS AND MAIN RESULTS: The patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia. A multiple logistic regression model demonstrated that receiving methylene blue was an independent predictor of in-hospital mortality (p value: 0.007, OR 4.26, 95% CI: 1.49-12.12), compilation of morbidities (p value: 0.001, OR 4.80, 95% CI: 1.85-12.43), and hyperbilirubinemia (p value:<0.001, OR 6.58, 95% CI: 2.91-14.89). Using propensity score matching, the association with morbidity was again seen but the association with mortality was not found. CONCLUSIONS: The current study identified the use of methylene blue as treatment for vasoplegia to be independently associated with poor outcomes. While further studies are required, a thorough risk-benefit analysis should be applied before using methylene blue and, perhaps, it should be relegated to rescue use and not as first-line therapy.
OBJECTIVES: The purpose of this study was to investigate whether patients who received methylene blue as treatment for vasoplegia during cardiac surgery with cardiopulmonary bypass had decreased morbidity and mortality. DESIGN: Retrospective analysis. SETTING: Single tertiary care university hospital. PARTICIPANTS: Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008. INTERVENTIONS: With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue. Two hundred twenty-six patients were identified who met the inclusion criteria for the study. Fifty-seven of these patients had received methylene blue for vasoplegia. The authors collected data on preoperative and intraoperative variables as well as outcomes. MEASUREMENTS AND MAIN RESULTS: The patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia. A multiple logistic regression model demonstrated that receiving methylene blue was an independent predictor of in-hospital mortality (p value: 0.007, OR 4.26, 95% CI: 1.49-12.12), compilation of morbidities (p value: 0.001, OR 4.80, 95% CI: 1.85-12.43), and hyperbilirubinemia (p value:<0.001, OR 6.58, 95% CI: 2.91-14.89). Using propensity score matching, the association with morbidity was again seen but the association with mortality was not found. CONCLUSIONS: The current study identified the use of methylene blue as treatment for vasoplegia to be independently associated with poor outcomes. While further studies are required, a thorough risk-benefit analysis should be applied before using methylene blue and, perhaps, it should be relegated to rescue use and not as first-line therapy.
Authors: J Hunter Mehaffey; Lily E Johnston; Robert B Hawkins; Eric J Charles; Leora Yarboro; John A Kern; Gorav Ailawadi; Irving L Kron; Ravi K Ghanta Journal: Ann Thorac Surg Date: 2017-05-24 Impact factor: 4.330
Authors: Paulo Roberto Barbosa Evora; Lafaiete Alves Junior; Cesar Augusto Ferreira; Antônio Carlos Menardi; Solange Bassetto; Alfredo José Rodrigues; Adilson Scorzoni Filho; Walter Vilella de Andrade Vicente Journal: Rev Bras Cir Cardiovasc Date: 2015 Jan-Mar
Authors: Othmar Kofler; Maximilian Simbeck; Roland Tomasi; Ludwig Christian Hinske; Laura Valentina Klotz; Florian Uhle; Frank Born; Maximilian Pichlmaier; Christian Hagl; Markus Alexander Weigand; Bernhard Zwißler; Vera von Dossow Journal: J Clin Med Date: 2022-02-20 Impact factor: 4.241
Authors: Walter Petermichl; Michael Gruber; Ina Schoeller; Kwahle Allouch; Bernhard M Graf; York A Zausig Journal: J Cardiothorac Surg Date: 2021-07-28 Impact factor: 1.637
Authors: Fabio Luis-Silva; Mayra Gonçalves Menegueti; Corina Dos Reis Sepeda; Bruno C Petroski-Moraes; Lucas Sato; Leandro Moreira Peres; Christiane Becari; Anibal Basile-Filho; Paulo R B Evora; Olindo Assis Martins-Filho; Maria Auxiliadora-Martins Journal: Medicine (Baltimore) Date: 2022-01-21 Impact factor: 1.889